Press Releases

Celleron Therapeutics enters into a license agreement with Roche to improve the lives of patients living with tenosynovial giant cell tumour

Aug 12, 2020

Oxford, 12th August 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the signing

Read More

Celleron Therapeutics Chief Medical Officer Prof David Kerr Leads Opening of University of Oxford-Sichuan University Huaxi Joint Centre for Gastrointestinal Cancer

May 18, 2020

Oxford, UK / Sichuan, China, 15 May 2020 Today marks the launch of the University of Oxford-Sichuan University Huaxi Joint

Read More

Celleron Therapeutics’ clinical trial initiated in China with partner Nuance Biotech

Mar 2, 2020

Oxford, UK, 2nd March 2020 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced that

Read More

Celleron Therapeutics reports that CXD101 reduces GI side effects of nivolumab

Jan 13, 2020

Lack of colitis side effect with CXD101 and nivolumab combination therapy in CAROSELL Phase II clinical trial of MSS CRC

Read More

Celleron Therapeutics announces James Noble as a New Board Member

Oct 21, 2019

Oxford, UK,21 October 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today

Read More

Celleron Therapeutics presents CXD101 and nivolumab combination therapy Phase II clinical trial (CAROSELL) at ESMO 2019

Sep 30, 2019

Oxford, UK, 30th September 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients,

Read More

Celleron Therapeutics to present CXD101 and nivolumab combination therapy Phase II clinical trial (CAROSELL) at ESMO 2019

Aug 6, 2019

Oxford, UK, 6 August 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients,

Read More

Celleron Therapeutics Data Committee approves continuation of CXD101 and nivolumab combination therapy CAROSELL Phase II clinical trial in MSS CRC patients

Jun 17, 2019

Oxford, UK, 17 Jun 2019 – Celleron Therapeutics, a UK-based company developing personalised medicines for cancer patients, announced today approval

Read More

Celleron Therapeutics Presents at the 15th Shanghai International Colorectal Cancer Symposium (SICCS)

Jun 15, 2019

Oxford UK, 15 June 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that

Read More

Celleron Therapeutics discusses China as a Biotech Hot Spot, at BioEquity Europe 2019

May 24, 2019

Oxford, UK, 22 May 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, participated in the

Read More